ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Cambrex Gets FDA Warning Letter

by Ann M. Thayer
August 31, 2009 | APPEARED IN VOLUME 87, ISSUE 35

Cambrex says it has received a warning letter from FDA connected with a March 2009 inspection of the company’s generic active pharmaceutical ingredient manufacturing (API) facility in Milan, Italy. The custom manufacturing firm says the issues raised relate primarily to the collection and maintenance of lab data. Cambrex says it has already addressed some of the problems and is working to resolve the rest. Failure to act would mean FDA could withhold any product approvals listing the facility as the API source or prevent entry into the U.S. of products manufactured at the site.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment